Evidence map›Paper›PMID 40188947›Full record

ArticleThe Journal of molecular diagnostics : JMD2025

Robust Assessment of Homologous Recombination Deficiency Genomic Instability by OncoScan Microarrays.

Ariadna Lara Gutierrez, Iris Halbwedl, Stefan Sauer, Peter Regitnig, Edgar Petru, Rita Seeböck, Susanne Schubert, Cornelia Peternell, Koppány Bodó, Kurt Prein and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Evaluation of homologous recombination testing in ovarian carcinoma.Virchows Archiv : an international journal of pathology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ariadna Lara GutierrezDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Iris HalbwedlDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Stefan SauerDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Peter RegitnigDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Edgar PetruDivision of Gynaecology, Medical University of Graz, Graz, Austria.
Rita SeeböckInstitute of Clinical Pathology and Molecular Pathology of the Lower Austria Central Region (University Hospital St. Pölten), Karl Landsteiner University of Health Sciences, Krems, Austria.
Susanne SchubertDivision of Gynaecology and Obstetrics, University Hospital St. Pölten, St. Pölten, Austria; Karl Landsteiner University of Health Sciences, Krems, Austria.
Cornelia PeternellDivision of Gynaecology and Obstetrics, Hospital Hochsteiermark, Leoben, Austria.
Koppány BodóInstitute of Pathology, Hospital Hochsteiermark, Leoben, Austria.
Kurt PreinInstitute of Pathology, Hospital Hochsteiermark, Leoben, Austria.
Karl KashoferDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria. Electronic address: karl.kashofer@medunigraz.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genomic instability scars are markers for detecting homologous recombination deficiency (HRD) status in patients with ovarian cancer and predicting the response to poly (ADP-ribose) polymerase inhibitor treatment. Currently, only a few reliable and validated assays are available, with the Myriad myChoice CDx being the most commonly used commercial assay for genomic instability scar score determination. Given the need for a more straightforward, accessible, and reliable method for detecting genomic instability scars methods, in this work, we describe the feasibility of using the microarray OncoScan copy number variant assay and open-source software packages to quantify genomic instability scores, and the development of an open-access online platform for genomic instability score calculation. The laboratory-developed test accurately classified homologous recombination-proficient and recombination-deficient samples based on genomic instability scores derived from the OncoScan copy number variant assay. Internally evaluated genomic instability scores demonstrated a 92% overall agreement and a higher sample success rate compared with externally analyzed genomic instability scar scores. The availability of HRD determination has doubled the number of patients eligible for poly (ADP-ribose) polymerase therapy. The assay can be conveniently performed on individual samples, and the open-access online platform facilitates HRD determination without the need for specialized bioinformatics support.

Indexed as

Genomic InstabilityHomologous RecombinationOligonucleotide Array Sequence AnalysisOvarian NeoplasmsDNA Copy Number VariationsFemaleHumansPoly(ADP-ribose) Polymerase InhibitorsSoftwarePoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID40188947
PMCPMC12163384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.